Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free ENTX Stock Alerts

Entera Bio (ENTX) Financials

Entera Bio logo
$2.00 +0.22 (+12.36%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$2.01 +0.01 (+0.50%)
As of 07/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Entera Bio

Annual Income Statements for Entera Bio

This table shows Entera Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Consolidated Net Income / (Loss)		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Net Income / (Loss) Continuing Operations		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Total Pre-Tax Income 		-1.20 -11 -10 -11 -11 -12 -13 -8.86 -9.53 -11
Total Operating Income		 -5.37 -11 -11 -11 -11 -12 -13 -8.89 -9.59 -12
Total Gross Profit		 0.00 0.00 0.50 0.03 0.07 0.20 0.03 0.00 0.01 0.00
Total Revenue		 0.00 0.00 0.50 0.24 0.37 0.57 0.13 0.00 0.18 0.04
Operating Revenue		 0.00 0.00 0.50 0.24 0.37 0.57 0.13 0.00 0.18 0.04
Total Cost of Revenue		 0.00 0.00 0.00 0.21 0.30 0.37 0.10 0.00 0.17 0.04
Operating Cost of Revenue		 - 0.00 0.00 0.21 0.30 0.37 0.10 0.00 0.17 0.04
Total Operating Expenses		 5.37 11 11 11 11 12 13 8.89 9.59 12
Selling, General & Admin Expense		 2.72 8.58 2.84 4.28 4.85 5.69 7.25 4.43 5.10 5.53
Research & Development Expense		 2.65 2.77 8.52 7.20 6.38 6.77 5.85 4.51 4.50 6.00
Total Other Income / (Expense), net		 4.17 0.15 0.56 0.66 -0.03 -0.03 0.08 0.03 0.06 0.09
Other Income / (Expense), net		 -0.14 -0.11 0.03 -0.08 -0.03 -0.03 0.08 0.03 0.06 0.09
Income Tax Expense		 - - 0.00 0.00 0.02 -0.06 0.14 0.03 0.01 0.00
Basic Earnings per Share		 - $2.49 $1.30 $0.89 $0.67 $0.47 $0.45 $0.31 $0.25 $0.25
Weighted Average Basic Shares Outstanding		 4.47M 4.49M 7.96M 12.15M 18.42M 26.13M 28.81M 29.01M 37.65M 46.19M
Diluted Earnings per Share		 $0.78 $2.49 $1.31 $0.89 $0.67 $0.47 $0.45 $0.31 $0.25 $0.25
Weighted Average Diluted Shares Outstanding		 6.76M 4.49M 7.98M 12.15M 18.42M 26.13M 28.81M 29.01M 37.65M 46.19M
Weighted Average Basic & Diluted Shares Outstanding		 - - 11.46M 18.20M 18.42M 26.13M 28.81M 35.48M 45.42M 46.62M

Quarterly Income Statements for Entera Bio

This table shows Entera Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.38 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51
Consolidated Net Income / (Loss)		 -2.38 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51
Net Income / (Loss) Continuing Operations		 -2.38 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51
Total Pre-Tax Income 		-2.35 -2.00 -2.02 -2.15 -3.02 -2.34 -2.57 -2.66 -3.20 -3.02 -3.51
Total Operating Income		 -2.39 -1.96 -2.06 -2.17 -3.02 -2.34 -2.56 -2.67 -3.26 -3.04 -3.54
Total Gross Profit		 0.00 - 0.00 0.01 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.06 0.04 0.08 0.04 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.06 0.04 - 0.04 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.05 0.04 0.08 0.04 0.00 0.00 - 0.00
Operating Cost of Revenue		 0.00 - 0.00 0.05 0.04 - 0.04 0.00 0.00 - 0.00
Total Operating Expenses		 2.39 1.94 2.06 2.17 3.02 2.34 2.56 2.67 3.26 3.04 3.54
Selling, General & Admin Expense		 1.03 0.97 1.33 1.09 1.54 1.14 1.44 1.15 1.61 1.32 1.29
Research & Development Expense		 1.37 1.00 0.74 1.09 1.48 1.20 1.12 1.52 1.64 1.72 2.25
Total Other Income / (Expense), net		 0.04 -0.03 0.05 0.02 0.00 -0.01 -0.00 0.01 0.06 0.03 0.03
Other Income / (Expense), net		 0.04 -0.03 0.05 0.02 0.00 -0.01 -0.00 0.01 0.06 0.03 0.03
Basic Earnings per Share		 $0.08 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07
Weighted Average Basic Shares Outstanding		 28.81M 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M
Diluted Earnings per Share		 $0.08 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07
Weighted Average Diluted Shares Outstanding		 28.81M 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M
Weighted Average Basic & Diluted Shares Outstanding		 28.81M 35.48M 35.79M 36.32M 36.83M 45.42M 45.45M 45.66M 45.86M 46.62M 49.23M

Annual Cash Flow Statements for Entera Bio

This table details how cash moves in and out of Entera Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.96 7.58 -4.24 7.68 -6.56 16 -13 -1.29 -2.35 6.20
Net Cash From Operating Activities		 -4.22 -4.38 -14 -4.98 -11 -9.06 -12 -7.31 -6.82 -7.37
Net Cash From Continuing Operating Activities		 -4.22 -4.38 -14 -4.98 -11 -9.06 -12 -7.31 -6.81 -7.37
Net Income / (Loss) Continuing Operations		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Consolidated Net Income / (Loss)		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Depreciation Expense		 0.04 0.04 0.05 0.24 0.06 0.05 0.06 0.06 0.05 0.03
Non-Cash Adjustments To Reconcile Net Income		 -3.43 5.85 -3.00 4.89 0.95 1.88 2.17 1.69 2.56 2.78
Changes in Operating Assets and Liabilities, net		 0.38 0.93 -0.51 0.70 -0.35 1.19 -1.66 -0.17 0.13 1.26
Net Cash From Investing Activities		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.10 -0.02 -0.00 -0.11
Net Cash From Continuing Investing Activities		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.10 -0.02 -0.00 -0.11
Purchase of Property, Plant & Equipment		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.05 -0.02 -0.00 -0.11
Net Cash From Financing Activities		 7.22 11 9.62 13 4.05 25 0.01 6.04 4.48 14
Net Cash From Continuing Financing Activities		 7.22 12 9.62 13 4.05 25 0.01 6.04 4.48 14
Repayment of Debt		 - - - - - - 0.00 -0.58 -0.32 -0.26
Issuance of Common Equity		 - - - - 3.19 22 0.00 6.62 3.96 6.25
Other Financing Activities, net		 - 0.00 0.00 0.14 0.07 3.58 0.01 0.00 0.84 7.72
Effect of Exchange Rate Changes		 - - - - - - - - 0.00 -0.04
Cash Interest Received		 - 0.00 0.00 0.08 - - 0.00 0.02 0.07 0.18

Quarterly Cash Flow Statements for Entera Bio

This table details how cash moves in and out of Entera Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.53 3.41 -1.83 -0.12 -2.14 1.75 12 -1.71 -2.30 -1.72 -2.96
Net Cash From Operating Activities		 -1.53 -2.62 -1.86 -1.34 -2.15 -1.47 -1.40 -1.63 -2.50 -1.83 -3.09
Net Cash From Continuing Operating Activities		 -1.53 -2.62 -1.86 -1.34 -2.14 -1.47 -1.40 -1.63 -2.49 -1.84 -3.10
Net Income / (Loss) Continuing Operations		 -2.38 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51
Consolidated Net Income / (Loss)		 -2.38 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.37 0.34 0.46 0.59 0.94 0.57 0.60 0.53 0.91 0.74 0.67
Changes in Operating Assets and Liabilities, net		 0.47 -0.97 -0.31 0.21 -0.08 0.31 0.56 0.49 -0.21 0.43 -0.27
Net Cash From Investing Activities		 - -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00
Net Cash From Continuing Investing Activities		 - -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00
Purchase of Property, Plant & Equipment		 - -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00
Net Cash From Financing Activities		 - 6.03 0.03 1.22 0.01 3.22 13 -0.05 0.25 0.17 0.13
Net Cash From Continuing Financing Activities		 - 6.03 0.03 1.22 0.01 3.22 13 -0.05 0.25 0.17 0.13
Repurchase of Common Equity		 - - 0.00 -0.02 - - -0.19 -0.08 -0.00 - 0.00
Issuance of Common Equity		 - 6.61 0.00 0.62 - 3.36 6.18 - 0.07 - 0.00
Other Financing Activities, net		 - - 0.03 0.62 0.01 0.18 7.34 0.02 0.18 0.17 0.13
Effect of Exchange Rate Changes		 - - - - - - 0.00 - - -0.07 0.00
Cash Interest Received		 - 0.02 0.04 0.03 0.00 0.00 0.00 0.06 0.07 0.05 0.04

Annual Balance Sheets for Entera Bio

This table presents Entera Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 13 13 17 9.72 26 13 12 9.39 16
Total Current Assets		 12 12 16 9.11 25 13 11 8.97 15
Cash & Equivalents		 12 7.51 15 8.59 25 12 11 8.66 7.11
Restricted Cash		 - - - - - - - 0.00 7.78
Accounts Receivable		 0.00 0.73 0.28 0.26 0.18 0.25 0.00 0.13 0.00
Prepaid Expenses		 - - - - - - - - 0.42
Plant, Property, & Equipment, net		 0.21 0.22 0.20 0.19 0.16 0.14 0.10 0.06 0.13
Total Noncurrent Assets		 0.65 0.65 0.61 0.42 0.50 0.14 0.41 0.36 0.56
Employee Benefit Assets		 - - - 0.05 0.05 0.01 0.01 0.01 0.01
Other Noncurrent Operating Assets		 - - - 0.37 0.24 0.09 0.39 0.36 0.56
Total Liabilities & Shareholders' Equity		 13 13 17 9.72 26 13 12 9.39 16
Total Liabilities		 45 3.23 4.78 2.21 3.42 1.37 1.38 1.31 2.89
Total Current Liabilities		 2.02 3.16 4.59 1.84 3.16 1.34 1.09 1.18 2.20
Accounts Payable		 1.42 1.56 1.70 0.16 0.17 0.02 0.08 0.13 0.45
Accrued Expenses		 - - - 1.33 2.80 1.23 0.87 0.87 1.53
Other Current Liabilities		 0.00 0.23 0.44 0.19 0.18 0.09 0.13 0.17 0.23
Total Noncurrent Liabilities		 43 0.07 0.19 0.37 0.26 0.03 0.29 0.13 0.69
Long-Term Debt		 - - - - - - - - 0.39
Noncurrent Employee Benefit Liabilities		 - - - 0.13 0.14 0.03 0.03 0.03 0.04
Other Noncurrent Operating Liabilities		 - - - 0.24 0.12 0.00 0.26 0.10 0.26
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -34 10 12 7.51 23 12 10 8.08 13
Total Preferred & Common Equity		 -34 10 12 7.51 23 12 10 8.08 13
Total Common Equity		 -32 10 12 7.51 23 12 10 8.08 13
Common Stock		 0.00 49 63 78 105 107 115 122 138
Retained Earnings		 -42 -52 -63 -70 -82 -95 -104 -114 -125
Accumulated Other Comprehensive Income / (Loss)		 - 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04

Quarterly Balance Sheets for Entera Bio

This table presents Entera Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 8.57 10 10 7.74 22 20 17 13
Total Current Assets		 8.02 9.75 9.60 7.34 21 19 17 12
Cash & Equivalents		 7.59 9.19 9.06 6.92 13 11 8.57 4.14
Restricted Cash		 - - - - 8.00 8.02 8.03 7.79
Accounts Receivable		 0.00 - 0.06 0.04 0.13 0.00 0.00 0.00
Prepaid Expenses		 0.43 0.56 0.48 0.38 0.52 0.44 0.41 0.57
Plant, Property, & Equipment, net		 0.11 0.09 0.08 0.07 0.06 0.08 0.11 0.13
Total Noncurrent Assets		 0.44 0.40 0.36 0.34 0.33 0.28 0.29 0.51
Employee Benefit Assets		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Other Noncurrent Operating Assets		 0.42 0.38 0.34 0.32 0.32 0.27 0.28 0.50
Total Liabilities & Shareholders' Equity		 8.57 10 10 7.74 22 20 17 13
Total Liabilities		 2.33 1.38 1.50 1.29 2.22 2.41 2.17 2.44
Total Current Liabilities		 2.03 1.12 1.29 1.11 1.62 1.84 1.57 1.58
Accounts Payable		 0.56 0.07 0.07 0.18 0.13 0.38 0.22 0.27
Accrued Expenses		 1.33 0.90 1.07 0.77 1.32 1.27 1.19 1.12
Other Current Liabilities		 0.13 0.15 0.16 0.16 0.17 0.19 0.17 0.19
Total Noncurrent Liabilities		 0.30 0.26 0.21 0.18 0.60 0.57 0.60 0.87
Long-Term Debt		 - - - - 0.52 0.52 0.53 0.57
Noncurrent Employee Benefit Liabilities		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04
Other Noncurrent Operating Liabilities		 0.27 0.22 0.18 0.15 0.05 0.01 0.04 0.26
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.24 8.86 8.53 6.45 19 17 15 11
Total Preferred & Common Equity		 6.24 8.86 8.53 6.45 19 17 15 11
Total Common Equity		 6.24 8.86 8.53 6.45 19 17 15 11
Common Stock		 109 115 117 118 136 136 138 140
Retained Earnings		 -102 -106 -109 -112 -116 -119 -122 -129
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04

Annual Metrics And Ratios for Entera Bio

This table displays calculated financial ratios and metrics derived from Entera Bio's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 11,459,780.00 18,202,237.00 23,738,642.00 23,738,642.00 28,809,922.00 28,813,952.00 - 45,857,242.00
DEI Adjusted Shares Outstanding		 0.00 0.00 11,459,780.00 18,202,237.00 23,738,642.00 23,738,642.00 28,809,922.00 28,813,952.00 - 45,857,242.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.90 -0.59 -0.47 -0.51 -0.45 -0.31 - -0.25
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -52.80% 54.66% 56.44% -76.53% -100.00% 0.00% -76.80%
EBITDA Growth		 0.00% -108.31% 5.54% -4.89% 1.48% -9.52% -5.55% 31.59% -7.69% -20.34%
EBIT Growth		 0.00% -107.77% 5.42% -6.57% 2.96% -9.38% -5.62% 31.50% -7.53% -20.07%
NOPAT Growth		 0.00% -111.35% 4.25% -5.46% 2.50% -9.39% -6.55% 31.70% -7.81% -20.28%
Net Income Growth		 0.00% -833.86% 7.98% -4.77% -3.90% -8.66% -7.25% 31.99% -7.33% -19.89%
EPS Growth		 0.00% 219.23% -47.39% -32.06% -24.72% -29.85% -4.26% -31.11% -19.35% 0.00%
Operating Cash Flow Growth		 0.00% -3.87% -214.16% 63.84% -112.20% 14.15% -37.91% 41.52% 6.73% -8.10%
Free Cash Flow Firm Growth		 0.00% 0.00% -40.68% 72.37% -149.30% 6.28% -48.93% 43.53% -10.04% -7.38%
Invested Capital Growth		 0.00% 0.00% 3,443.52% -127.78% -1.88% -114.87% 76.15% -14.05% 8.37% -139.48%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.98% -100.00% 82.83% -66.13%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.45% 10.95% -3.84% -6.30%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.40% 10.92% -3.80% -6.24%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.27% 11.05% -4.06% -6.51%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.53% 10.47% -3.96% -6.10%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.76% -8.82% -3.85% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.85% -9.04% 14.43% -5.23%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.60% 7.79% -0.87%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,945.45% 53.08% -25.27% -65.16%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 11.02% 17.81% 34.68% 24.63% 0.00% 4.97% 0.00%
EBITDA Margin		 0.00% 0.00% -2,154.60% -4,788.14% -3,050.14% -2,135.38% -9,604.48% 0.00% -5,238.12% -27,164.29%
Operating Margin		 0.00% 0.00% -2,172.20% -4,853.39% -3,059.73% -2,139.58% -9,714.18% 0.00% -5,295.58% -27,450.00%
EBIT Margin		 0.00% 0.00% -2,165.40% -4,888.98% -3,067.40% -2,144.66% -9,652.24% 0.00% -5,263.54% -27,235.71%
Profit (Net Income) Margin		 0.00% 0.00% -2,060.80% -4,574.15% -3,072.88% -2,134.33% -9,754.48% 0.00% -5,271.27% -27,235.71%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.18% 99.52% 101.06% 100.33% 100.15% 100.00%
Interest Burden Percent		 21.76% 97.81% 95.17% 93.56% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -386.41% -580.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -405.52% -551.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 471.10% 482.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 32.50% 84.68% -97.98% -115.46% -81.04% -76.17% -80.30% -103.34% -108.01%
Cash Return on Invested Capital (CROIC)		 0.00% -14,903.89% -575.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -81.35% -76.81% -84.74% -68.59% -66.13% 0.00% -90.07% -90.13%
Return on Assets (ROA)		 0.00% 0.00% -77.42% -71.86% -84.89% -68.26% -66.84% 0.00% -90.20% -90.13%
Return on Common Equity (ROCE)		 0.00% 29.77% 74.61% -97.98% -115.46% -81.04% -76.17% -80.30% -103.34% -108.01%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 32.50% -101.86% -90.57% -149.35% -54.01% -111.20% -85.59% -118.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.76 -7.94 -7.60 -8.02 -7.82 -8.55 -9.11 -6.22 -6.71 -8.07
NOPAT Margin		 0.00% 0.00% -1,520.54% -3,397.37% -2,141.81% -1,497.71% -6,799.93% 0.00% -3,706.91% -19,215.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 18.85% 19.11% -28.82% -31.50% -21.71% -21.28% -22.85% -28.78% -29.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -59.92% -83.04% -59.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 88.98% 82.19% 65.32% 75.37% 0.00% 95.03% 100.00%
SG&A Expenses to Revenue		 0.00% 0.00% 568.60% 1,813.98% 1,329.04% 996.50% 5,412.69% 0.00% 2,814.92% 13,154.76%
R&D to Revenue		 0.00% 0.00% 1,703.60% 3,050.42% 1,748.49% 1,185.81% 4,364.18% 0.00% 2,485.64% 14,295.24%
Operating Expenses to Revenue		 0.00% 0.00% 2,272.20% 4,864.41% 3,077.53% 2,174.26% 9,776.87% 0.00% 5,300.55% 27,450.00%
Earnings before Interest and Taxes (EBIT)		 -5.51 -11 -11 -12 -11 -12 -13 -8.86 -9.53 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.48 -11 -11 -11 -11 -12 -13 -8.80 -9.48 -11
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.41 2.18 2.65 3.26 1.79 1.68 9.88 6.84
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.57 2.30 2.65 3.26 1.79 1.68 9.88 6.84
Price to Revenue (P/Rev)		 0.00 0.00 48.70 110.14 54.49 128.84 156.94 0.00 440.99 2,133.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 4.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 33.69 46.32 30.95 85.24 65.08 0.00 393.14 1,788.59
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.03
Financial Leverage		 0.00 -1.00 -1.16 -0.87 -1.11 -1.11 -1.08 -1.05 -1.07 -1.09
Leverage Ratio		 0.00 -0.39 -1.09 1.36 1.36 1.19 1.14 1.12 1.15 1.20
Compound Leverage Factor		 0.00 -0.38 -1.04 1.28 1.36 1.19 1.14 1.12 1.15 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 91.60% 100.00% 98.99% 100.00% 100.00% 100.00% 100.00% 100.00% 97.09%
Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 1.33 0.00 0.00 0.00 0.00 0.00 1.27
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.03
Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 -0.05
Net Debt to NOPAT		 0.00 0.00 0.00 1.88 0.00 0.00 0.00 0.00 0.00 1.80
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 -0.05
Altman Z-Score		 0.00 -6.16 -2.74 -3.49 -7.59 7.95 -3.18 -6.30 17.24 6.24
Noncontrolling Interest Sharing Ratio		 0.00% 8.40% 11.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 6.15 3.94 3.41 4.95 8.01 9.58 10.32 7.63 6.94
Quick Ratio		 0.00 5.81 2.60 3.37 4.81 7.93 9.36 10.10 7.47 3.23
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.05 -11 -3.13 -7.80 -7.31 -11 -6.15 -6.76 -7.26
Operating Cash Flow to CapEx		 -10,285.37% -8,588.24% -20,235.29% -12,437.50% -19,918.87% -53,311.76% -26,593.62% -43,000.00% -227,266.67% -6,887.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.04 0.02 0.03 0.03 0.01 0.00 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.47 1.37 2.61 0.62 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 2.32 1.11 1.85 3.28 0.91 0.00 2.31 0.44
Accounts Payable Turnover		 0.00 0.00 0.00 0.13 0.32 2.26 1.10 0.00 1.60 0.14
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 775.63 266.50 139.99 584.27 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 2,839.18 1,136.37 161.46 330.67 0.00 228.13 2,520.24
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -2,063.55 -869.87 -21.47 253.60 0.00 -228.13 -2,520.24
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.11 3.83 -1.06 -1.08 -2.33 -0.56 -0.63 -0.58 -1.39
Invested Capital Turnover		 0.00 0.00 0.25 0.17 -0.34 -0.33 -0.09 0.00 -0.30 -0.04
Increase / (Decrease) in Invested Capital		 0.00 0.11 3.72 -4.89 -0.02 -1.24 1.77 -0.08 0.05 -0.81
Enterprise Value (EV)		 0.00 -0.55 17 11 11 49 8.72 6.39 71 75
Market Capitalization		 11 11 24 26 20 74 21 17 80 90
Book Value per Share		 $0.00 ($7.03) $1.27 $1.04 $0.41 $0.95 $0.41 $0.36 $0.22 $0.29
Tangible Book Value per Share		 $0.00 ($7.17) $1.19 $0.99 $0.41 $0.95 $0.41 $0.36 $0.22 $0.29
Total Capital		 0.00 -34 10 12 7.51 23 12 10 8.08 13
Total Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.39
Total Long-Term Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.39
Net Debt		 0.00 -12 -7.51 -15 -8.59 -25 -12 -11 -8.66 -14
Capital Expenditures (CapEx)		 0.04 0.05 0.07 0.04 0.05 0.02 0.05 0.02 0.00 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.35 1.80 -4.14 -1.33 -2.72 -0.80 -0.85 -0.86 -1.79
Debt-free Net Working Capital (DFNWC)		 0.00 10 9.31 11 7.27 22 12 10 7.80 13
Net Working Capital (NWC)		 0.00 10 9.31 11 7.27 22 12 10 7.80 13
Net Nonoperating Expense (NNE)		 -2.56 3.26 2.70 2.78 3.40 3.64 3.96 2.67 2.83 3.37
Net Nonoperating Obligations (NNO)		 0.00 35 -6.29 -13 -8.59 -25 -12 -11 -8.66 -14
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.05 0.24 0.06 0.05 0.06 0.06 0.05 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 360.00% -1,754.66% -363.01% -477.06% -597.76% 0.00% -477.35% -4,257.14%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,861.20% 4,679.66% 1,991.23% 3,882.31% 8,588.06% 0.00% 4,307.18% 31,178.57%
Net Working Capital to Revenue		 0.00% 0.00% 1,861.20% 4,679.66% 1,991.23% 3,882.31% 8,588.06% 0.00% 4,307.18% 31,178.57%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.30 $0.89 $0.54 $0.47 $0.45 $0.31 $0.25 $0.25
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 7.96M 12.15M 18.42M 28.80M 28.81M 29.01M 37.65M 46.19M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.31 $0.89 $0.55 $0.47 $0.45 $0.31 $0.25 $0.25
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 7.98M 12.15M 18.56M 28.80M 28.81M 29.01M 37.65M 46.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.47 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 11.46M 18.20M 23.74M 26.13M 28.81M 35.48M 45.42M 46.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.76 -7.94 -7.60 -8.02 -7.82 -8.55 -9.11 -6.22 -6.71 -8.07
Normalized NOPAT Margin		 0.00% 0.00% -1,520.54% -3,397.37% -2,141.81% -1,497.71% -6,799.93% 0.00% -3,706.91% -19,215.00%
Pre Tax Income Margin		 0.00% 0.00% -2,060.80% -4,574.15% -3,067.40% -2,144.66% -9,652.24% 0.00% -5,263.54% -27,235.71%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Entera Bio

This table displays calculated financial ratios and metrics derived from Entera Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 28,813,952.00 28,813,952.00 35,481,341.00 35,785,309.00 36,324,579.00 - 45,420,676.00 45,452,167.00 45,663,381.00 45,857,242.00 46,622,239.00
DEI Adjusted Shares Outstanding		 28,813,952.00 28,813,952.00 35,481,341.00 35,785,309.00 36,324,579.00 - 45,420,676.00 45,452,167.00 45,663,381.00 45,857,242.00 46,622,239.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.08 -0.07 -0.06 -0.06 -0.08 - -0.06 -0.06 -0.07 -0.07 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00% 0.00% -100.00%
EBITDA Growth		 18.24% 35.33% 7.90% 7.62% -28.85% -17.71% -27.69% -24.13% -6.05% -28.98% -36.69%
EBIT Growth		 18.20% 35.25% 7.90% 7.74% -28.55% -17.49% -27.27% -23.82% -5.93% -28.67% -36.54%
NOPAT Growth		 16.72% 36.02% 6.78% 7.08% -26.61% -19.05% -24.30% -23.23% -7.78% -30.17% -38.08%
Net Income Growth		 22.43% 34.27% 7.90% 7.74% -26.99% -18.20% -27.27% -23.82% -5.93% -27.91% -36.54%
EPS Growth		 -27.27% -30.00% -37.50% -25.00% 0.00% -14.29% 20.00% 0.00% -12.50% 0.00% 16.67%
Operating Cash Flow Growth		 46.85% -30.13% -15.72% 14.37% -41.25% 43.94% 24.60% -22.17% -16.16% -24.95% -120.09%
Free Cash Flow Firm Growth		 83.34% 66.93% -32.81% -156.71% -803.28% -30.31% 16.62% 31.45% 36.64% 21.82% -72.32%
Invested Capital Growth		 -12,163.64% -14.05% 46.64% 41.97% 65.68% 8.37% -108.28% -108.59% -81.64% -139.48% 0.88%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -26.32% 95.24% -48.78% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -1.13% 15.15% -1.11% -6.49% -41.05% 22.49% -9.69% -3.52% -20.50% 5.73% -16.25%
EBIT Q/Q Growth		 -1.08% 15.11% -1.10% -6.35% -40.84% 22.41% -9.51% -3.47% -20.48% 5.75% -16.21%
NOPAT Q/Q Growth		 -2.40% 17.73% -5.04% -5.00% -39.54% 22.64% -9.67% -4.10% -22.04% 6.57% -16.34%
Net Income Q/Q Growth		 -2.32% 16.14% -1.10% -6.35% -40.84% 21.95% -8.86% -3.47% -20.48% 5.75% -16.21%
EPS Q/Q Growth		 0.00% -12.50% -28.57% 20.00% 33.33% -25.00% 0.00% 0.00% 16.67% -14.29% 16.67%
Operating Cash Flow Q/Q Growth		 2.18% -71.61% 28.85% 28.30% -61.35% 31.89% 4.29% -16.17% -53.40% 26.74% -68.58%
Free Cash Flow Firm Q/Q Growth		 54.99% -290.16% -33.35% -9.61% -58.39% 43.72% 14.67% 9.89% -46.40% 30.55% -88.07%
Invested Capital Q/Q Growth		 -49.39% 53.08% 48.50% -60.74% 11.64% -25.27% -17.07% -60.97% 23.06% -65.16% 51.55%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 15.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% -3,743.86% -7,166.67% -2,845.12% -6,092.86% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% -3,798.25% -7,192.86% -2,850.00% -6,102.38% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% -3,763.16% -7,192.86% -2,858.54% -6,111.90% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -3,763.16% -7,192.86% -2,875.61% -6,111.90% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.23% 100.00% 100.00% 100.00% 100.00% 100.60% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -96.64% -80.30% -92.02% -101.84% -144.67% -103.34% -71.46% -82.22% -99.43% -108.01% -82.33%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -20.95% -87.34% -48.91% -85.62% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -20.95% -87.34% -49.21% -85.62% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -96.64% -80.30% -92.02% -101.84% -144.67% -103.34% -71.46% -82.22% -99.43% -108.01% -82.33%
Return on Equity Simple (ROE_SIMPLE)		 -159.22% 0.00% -98.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.67 -1.37 -1.44 -1.52 -2.11 -1.64 -1.79 -1.87 -2.28 -2.13 -2.48
NOPAT Margin		 0.00% 0.00% 0.00% -2,658.77% -5,035.00% -1,995.00% -4,271.67% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -6.47% -5.32% -5.77% -6.92% -12.50% -7.34% -5.29% -5.75% -8.01% -7.66% -6.54%
Return On Investment Capital (ROIC_SIMPLE)		 - -13.23% -16.29% -17.76% -32.78% -20.25% -9.02% -10.50% -14.46% -15.78% -22.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 84.21% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 1,908.77% 3,676.19% 1,385.37% 3,428.57% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 1,905.26% 3,516.67% 1,464.63% 2,673.81% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 3,814.04% 7,192.86% 2,850.00% 6,102.38% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.35 -2.00 -2.02 -2.15 -3.02 -2.34 -2.57 -2.66 -3.20 -3.02 -3.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.34 -1.98 -2.00 -2.13 -3.01 -2.33 -2.56 -2.65 -3.19 -3.01 -3.50
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.35 1.68 6.92 8.00 11.09 9.88 3.81 5.16 5.93 6.84 4.96
Price to Tangible Book Value (P/TBV)		 3.35 1.68 6.92 8.00 11.09 9.88 3.81 5.16 5.93 6.84 4.96
Price to Revenue (P/Rev)		 1,492.15 0.00 0.00 1,197.30 722.47 440.99 330.68 536.08 729.13 2,133.59 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 950.37 0.00 0.00 1,038.42 652.62 393.14 240.73 425.55 599.50 1,788.59 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.03 0.05
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.03 0.05
Financial Leverage		 -1.07 -1.05 -1.05 -1.09 -1.14 -1.07 -1.04 -1.06 -1.06 -1.09 -1.05
Leverage Ratio		 1.17 1.12 1.15 1.22 1.29 1.15 1.13 1.15 1.16 1.20 1.16
Compound Leverage Factor		 1.17 1.12 1.15 1.22 1.29 1.15 1.13 1.15 1.16 1.20 1.16
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.59% 2.95% 3.34% 2.91% 5.04%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.59% 2.95% 3.34% 2.91% 5.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.41% 97.05% 96.66% 97.09% 94.96%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.05 -0.05 -0.05 -0.03 -0.05
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 2.00 1.74 1.50 1.27 0.92
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.05 -0.05 -0.05 -0.03 -0.05
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.07 -0.07 -0.05 -0.06
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 2.84 2.48 2.12 1.80 1.30
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.07 -0.07 -0.05 -0.06
Altman Z-Score		 -11.42 -4.37 12.56 12.39 12.81 19.76 13.08 14.29 15.59 7.98 -0.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.95 10.32 8.70 7.42 6.61 7.63 13.07 10.47 10.83 6.94 7.93
Quick Ratio		 3.74 10.10 8.20 7.04 6.26 7.47 7.82 5.89 5.46 3.23 2.63
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.33 -1.30 -1.73 -1.89 -3.00 -1.69 -1.44 -1.30 -1.90 -1.32 -2.48
Operating Cash Flow to CapEx		 0.00% -52,340.00% 0.00% 0.00% 0.00% -48,900.00% -17,550.00% -5,624.14% -5,818.60% -6,788.89% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 1.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.11 0.00 0.00 0.58 1.14 2.31 3.10 2.14 1.39 0.44 0.00
Accounts Payable Turnover		 0.02 0.00 0.00 0.31 0.24 1.60 2.14 0.73 0.62 0.14 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 275.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 22,287.81 0.00 0.00 1,174.84 1,516.78 228.13 170.56 496.93 588.71 2,520.24 0.00
Cash Conversion Cycle (CCC)		 -22,287.81 0.00 0.00 -899.49 -1,516.78 -228.13 -170.56 -496.93 -588.71 -2,520.24 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.35 -0.63 -0.33 -0.52 -0.46 -0.58 -0.68 -1.09 -0.84 -1.39 -0.67
Invested Capital Turnover		 -0.02 0.00 0.00 -0.08 -0.11 -0.30 -0.44 -0.21 -0.19 -0.04 0.00
Increase / (Decrease) in Invested Capital		 -1.34 -0.08 0.29 0.38 0.89 0.05 -0.35 -0.57 -0.38 -0.81 0.01
Enterprise Value (EV)		 13 6.39 52 59 65 71 54 71 74 75 42
Market Capitalization		 21 17 61 68 72 80 74 89 90 90 53
Book Value per Share		 $0.22 $0.36 $0.25 $0.24 $0.18 $0.22 $0.43 $0.38 $0.33 $0.29 $0.23
Tangible Book Value per Share		 $0.22 $0.36 $0.25 $0.24 $0.18 $0.22 $0.43 $0.38 $0.33 $0.29 $0.23
Total Capital		 6.24 10 8.86 8.53 6.45 8.08 20 18 16 13 11
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.52 0.53 0.39 0.57
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.52 0.53 0.39 0.57
Net Debt		 -7.59 -11 -9.19 -9.06 -6.92 -8.66 -20 -18 -16 -14 -11
Capital Expenditures (CapEx)		 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.60 -0.85 -0.56 -0.76 -0.69 -0.86 -0.98 -1.41 -1.17 -1.79 -1.01
Debt-free Net Working Capital (DFNWC)		 5.99 10 8.63 8.30 6.23 7.80 20 17 15 13 11
Net Working Capital (NWC)		 5.99 10 8.63 8.30 6.23 7.80 20 17 15 13 11
Net Nonoperating Expense (NNE)		 0.71 0.62 0.57 0.63 0.91 0.72 0.77 0.79 0.92 0.89 1.03
Net Nonoperating Obligations (NNO)		 -7.59 -11 -9.19 -9.06 -6.92 -8.66 -20 -18 -16 -14 -11
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -11,400.00% 0.00% 0.00% -1,324.56% -692.93% -477.35% -438.57% -846.99% -940.32% -4,257.14% 0.00%
Debt-free Net Working Capital to Revenue		 42,778.57% 0.00% 0.00% 14,563.16% 6,291.92% 4,307.18% 8,787.00% 10,522.29% 12,448.39% 31,178.57% 0.00%
Net Working Capital to Revenue		 42,778.57% 0.00% 0.00% 14,563.16% 6,291.92% 4,307.18% 8,787.00% 10,522.29% 12,448.39% 31,178.57% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.08 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07
Adjusted Weighted Average Basic Shares Outstanding		 28.81M 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M
Adjusted Diluted Earnings per Share		 $0.08 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07
Adjusted Weighted Average Diluted Shares Outstanding		 28.81M 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.81M 35.48M 35.79M 36.32M 36.83M 45.42M 45.45M 45.66M 45.86M 46.62M 49.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.67 -1.37 -1.44 -1.52 -2.11 -1.64 -1.79 -1.87 -2.28 -2.13 -2.48
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -2,658.77% -5,035.00% -1,995.00% -4,271.67% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -3,763.16% -7,192.86% -2,858.54% -6,111.90% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Entera Bio (NASDAQ: ENTX) continues to operate as a pre-revenue biotech with no recurring product sales, meaning its financial story is still centered on cash burn, funding, and runway rather than profitability. The latest quarter shows another sizable operating loss, but the company still held a meaningful cash position, helped by prior financing and a large restricted cash balance.

  • The company ended Q1 2026 with $4.1 million in cash and equivalents plus $7.8 million in restricted cash, giving it a total cash-related balance of about $11.9 million.
  • Financing activity added $130,000 in Q1 2026, showing the company can still access some outside funding.
  • The Q1 2026 net loss of $3.5 million was only slightly worse than the $3.0 million loss in Q4 2025, suggesting expenses did not accelerate dramatically quarter over quarter.
  • Compared with Q1 2025, the quarterly cash burn has improved materially: operating cash outflow was -$3.1 million in Q1 2026 versus -$1.4 million in Q1 2025 after accounting for very large financing inflows last year.
  • Total equity remained positive at $10.7 million in Q1 2026, so the balance sheet still shows residual shareholder value.
  • Revenue remains effectively nonexistent: $0 in Q1 2026, consistent with the company’s development-stage status.
  • Research and development spending remained elevated at $2.25 million in Q1 2026, which is typical for a biotech advancing its pipeline but also keeps losses high.
  • The company had no investing cash outflow in Q1 2026, indicating minimal capital spending during the period.
  • Shares outstanding continue to trend higher over time, with weighted average basic shares rising to about 47.8 million in Q1 2026 from 43.4 million in Q1 2025, which can dilute per-share value.
  • Entera Bio generated a negative $3.1 million in operating cash flow in Q1 2026, underscoring that the business is still consuming cash to fund operations.
  • The company has now reported multiple consecutive quarterly net losses, with quarterly losses generally clustered around $2.0 million to $3.5 million over the last year and a half.
  • Cash and equivalents fell sharply from $8.6 million in Q3 2025 to $4.1 million in Q1 2026, indicating a meaningful drawdown in liquid cash.
  • Total current assets dropped to $12.5 million from $17.0 million in Q3 2025, reflecting a weaker short-term liquidity position.
  • Common equity declined to $10.7 million in Q1 2026 from $15.2 million in Q3 2025, showing that continued losses are eroding the balance sheet.

Longer-term trend: Entera Bio’s revenue has been inconsistent and minimal, while operating expenses have stayed high enough to keep the company deeply unprofitable. The balance sheet still appears serviceable, but the company’s future will likely depend on additional financing and progress in its biotech programs. For investors, the key question is whether upcoming clinical or partnership milestones can eventually justify the ongoing cash burn.

07/17/26 12:28 AM ETAI Generated. May Contain Errors.

Entera Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entera Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Entera Bio's net income appears to be on an upward trend, with a most recent value of -$11.44 million in 2025, rising from -$1.20 million in 2016. The previous period was -$9.54 million in 2024. See where experts think Entera Bio is headed by visiting Entera Bio's forecast page.

Entera Bio's total operating income in 2025 was -$11.53 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.53 million

Over the last 9 years, Entera Bio's total revenue changed from $0.00 in 2016 to $42 thousand in 2025, a change of 4,200,000.0%.

Entera Bio's total liabilities were at $2.89 million at the end of 2025, a 120.8% increase from 2024, and a 93.5% decrease since 2017.

In the past 8 years, Entera Bio's cash and equivalents has ranged from $7.11 million in 2025 to $24.89 million in 2021, and is currently $7.11 million as of their latest financial filing in 2025.

Over the last 9 years, Entera Bio's book value per share changed from 0.00 in 2016 to 0.29 in 2025, a change of 28.6%.


Related Companies

Financial statements for NASDAQ:ENTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel